Deciding Which Patients Are Best Suited for Various First-Line Pancreatic Cancer Treatment Options

Interview with the Innovators
Pancreatic Cancer Patient Education
Videos — November 21, 2024

Featuring:

Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ
Shubham Pant, MD
Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX
Michael Pishvaian, MD, PhD
Associate Professor of Oncology
Johns Hopkins University, Washington, DC

In this eighth installment, Shubham Pant, MD, and Michael Pishvaian, MD, PhD, discuss their approach on deciding which treatment options, FOLFIRINOX or NALIRIFOX, are best suited for the patients that they treat.

Featuring:

Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ
Shubham Pant, MD
Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX
Michael Pishvaian, MD, PhD
Associate Professor of Oncology
Johns Hopkins University, Washington, DC

Related Articles

Importance of Hospital Partnerships for Bispecific Agent Implementation
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Multiple Myeloma
Videos
Read Article
EHR Implementation of Bispecific Agents for Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Multiple Myeloma, Bispecific Antibodies
Videos
Read Article
Total Cost of Care for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
Read Article
Clinical Pathways in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article
Payer Policy Development for Bispecific Agents in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
Read Article
REMS Operational Considerations
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article
Adopting Bispecific Agents for Multiple Myeloma into Practice
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article
Team Education for Bispecific Usage in Multiple Myeloma
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators, Bispecific Antibodies
Videos
Read Article
Transitions of Care in Multiple Myeloma Patients
By Laura R. Bobolts, PharmD, BCOP; Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS; Hakan Kaya, MD; Lisa Raff, PharmD, MSPharm, BCPS, BCOP; Yonatan Resnick, PharmD
Interview with the Innovators
Videos
Read Article

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?